Pityriasis rosea (PR) is an acute papulosquamous cutaneous disorder that classically presents with a herald patch rapidly followed by a widespread rash along skin cleavage lines. Although the exact pathogenesis of PR is unknown, current evidence suggests that an inflammatory reaction due to a viral trigger may lead to the cutaneous manifestations. COVID-19 has been reported as one such viral trigger for PR. Previously, PR has been reported in temporal association with various viral inoculations. This article presents a case of PR in a 66-year-old black male 1 week after administration of the Pfizer-BioNTech COVID-19 vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828149 | PMC |
| http://dx.doi.org/10.1080/21645515.2021.1963173 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atypical Rash as a Presentation of Pityriasis Rosea in a 23-Month-Old.
Cureus
November 2024
Pediatric Emergency Medicine, The Brooklyn Hospital Center, New York, USA.
Pityriasis rosea is a self-limiting skin disorder that can occur in pediatric patients. We report an atypical presentation of a 23-month-old male with a generalized rash similar in appearance to pityriasis rosea. We then review the literature on pityriasis rosea and its application to pediatrics.
View Article and Find Full Text PDFEvidence of "Silent" Hepatitis B Virus Infection in Psoriasis, Vitiligo, and Cases: A Pilot Study.
Indian J Dermatol
October 2024
From the Division of Biological Sciences, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
Background: Psoriasis (PS), vitiligo (VT), and (PR) are chronic skin diseases often occurring as a consequence of exaggerated immune responses. These skin manifestations can be triggered as a result of the molecular mimicry between viral protein (s) and host protein (s), which could generate auto-antibodies. In addition, it can be hypothesised that skin diseases are manifestations of the reduced immunity that is observed in chronic hepatitis B virus (HBV)-infected individuals.
View Article and Find Full Text PDFComparative Efficacy of Different Pharmacological Treatments for Pityriasis Rosea: A Network Meta-Analysis.
J Clin Med
November 2024
Casa di Cura Villa Montallegro, 16100 Genoa, Italy.
Article Synopsis
- Pityriasis rosea (PR) is a skin condition that usually gets better on its own, often linked to reactivated human herpesviruses, causing mild rashes and itchiness.
- Traditional treatment focuses on reassuring patients to rest, but severe cases may require medication, prompting a study comparing various treatments.
- The analysis found that oral steroids and a combo with antihistamines were effective for itch relief, while acyclovir was the most effective for improving rash symptoms, making it the best option for more serious PR cases.
Drug-Induced Pityriasis Rosea: A Systematic Review.
J Cutan Med Surg
October 2024
Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Pityriasis rosea-like drug eruption secondary to deucravacitinib.
JAAD Case Rep
November 2024
Skin Health Institute, Carlton, Victoria, Australia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!